Related Articles
Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients
Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet